Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma - Episode 9

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

, , , , ,

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

EP. 1: Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification
EP. 2: Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion
EP. 3: Imaging and Staging Considerations in Renal Cell Carcinoma
EP. 4: Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen
EP. 5: Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma
EP. 6: Comparing Treatment Combinations in Renal Cell Carcinoma
EP. 7: Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC
EP. 8: Sequencing and Second-Line Therapy in RCC: Patient Scenario
Now Viewing
EP. 9: Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC
EP. 10: Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma
EP. 11: Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing
EP. 12: Triple Combination Therapies in RCC: Clinical Trial Insights
EP. 13: Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Related Content:

Optimizing Therapy for Patients with Advanced Renal Cell CarcinomaHuntsman Cancer Institute at the University of Utah The University of Texas MD Anderson Cancer Center
Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma
Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients
CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring